| Literature DB >> 34996576 |
Eric F Wagner, Robbert J Langwerden, Staci Leon Morris, Melissa K Ward, Mary Jo Trepka, Adriana L Campa, Melissa M Howard, Sara C Charles, Nana Aisha Garba, Michelle M Hospital.
Abstract
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic remains a public health priority, and vaccination is important for ending the pandemic. Racial and ethnic minorities are disproportionally affected by COVID-19 yet report high levels of vaccination hesitancy.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34996576 PMCID: PMC8590854 DOI: 10.1016/j.japh.2021.11.005
Source DB: PubMed Journal: J Am Pharm Assoc (2003) ISSN: 1086-5802
Figure 1Town halls’ attendee distribution by partnering community-based organizations. Note: This graph is a display of the proportions of all town hall participants to date (September 2021; N = 379). No missing values were reported. Abbreviations used: FIU, Florida International University; UHI, CommunityCare Clinic.
Figure 2Changes in vaccination likelihood from the beginning to end of town halls. Note: Includes only those participants who completed both pre- and postpolls during the 6 townhalls and who were not vaccinated (n = 69).
Demographic characteristics by vaccine status and hesitancy
| Characteristics | All | Vaccinated | Unvaccinated | Nonhesitant | Hesitant | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |||
| Age | 41.8 | 17.8 | 49.4 | 16.5 | 30.7 | 13.4 | < 0.001 | 29 | 12.6 | 34.4 | 14.7 | 0.1 |
| No. people in household | 3.1 | 4.7 | 3.2 | 6.1 | 3 | 1.2 | 0.021 | 3.2 | 1.2 | 2.7 | 1.2 | 0.13 |
| N | % | n | % | n | % | N | % | N | % | |||
| U.S. born | 83 | 56.8 | 45 | 51.7 | 38 | 64.4 | 0.12 | 27 | 67.5 | 11 | 57.9 | 0.47 |
| Home language not English | 86 | 59.3 | 52 | 59.8 | 34 | 58.6 | 0.8 | 22 | 56.4 | 12 | 63.2 | 0.73 |
| Female | 108 | 74.5 | 64 | 73.6 | 44 | 75.9 | 0.94 | 30 | 75 | 14 | 77.8 | 0.79 |
| Male | 34 | 23.4 | 21 | 24.1 | 13 | 22.4 | 0.94 | 9 | 22.5 | 4 | 22.2 | 0.79 |
| Race and ethnicity | ||||||||||||
| Black or African American | 30 | 20.4 | 15 | 17 | 15 | 25.4 | 0.22 | 8 | 20 | 7 | 36.8 | 0.17 |
| White | 97 | 66 | 59 | 67 | 38 | 64.4 | 0.74 | 27 | 67.5 | 11 | 57.9 | 0.47 |
| Other | 8 | 5.4 | 5 | 5.7 | 3 | 5.1 | 0.88 | 2 | 5 | 1 | 5.3 | 0.97 |
| Hispanic/Latinx and white | 61 | 41.5 | 39 | 44.3 | 22 | 37.3 | 0.4 | 13 | 32.5 | 9 | 47.4 | 0.27 |
| Hispanic/Latinx and Black | 6 | 4.1 | 3 | 3.4 | 3 | 5.1 | 0.62 | 2 | 5 | 1 | 5.3 | 0.97 |
| Hispanic/Latinx | 76 | 52.1 | 46 | 52.9 | 30 | 50.8 | 0.74 | 19 | 47.5 | 11 | 57.9 | 0.52 |
| Haitian | 6 | 4.2 | 1 | 1.2 | 5 | 8.6 | 0.04 | 4 | 10.3 | 1 | 5.3 | 0.53 |
| Income | ||||||||||||
| ≤ $19,999 | 19 | 13.1 | 10 | 11.6 | 9 | 15.3 | 0.52 | 7 | 17.5 | 2 | 10.6 | 0.96 |
| $20,000–$34,999 | 12 | 8.3 | 11 | 12.8 | 1 | 1.7 | 0.52 | 0 | 0 | 1 | 5.3 | 0.96 |
| $35,000–$74,999 | 39 | 26.9 | 24 | 27.9 | 15 | 25.5 | 0.52 | 8 | 20 | 7 | 36.8 | 0.96 |
| ≥ $75,000 | 40 | 27.5 | 26 | 30.3 | 14 | 23.8 | 0.52 | 10 | 25 | 4 | 21.1 | 0.96 |
| Prefer not to answer income | 35 | 24.1 | 15 | 17.4 | 20 | 33.9 | — | 15 | 37.5 | 5 | 26.3 | — |
Note: Percentages reflect valid percentages (denominator excludes missing responses but includes “prefer not to answer” responses), except for income for which the “prefer not to answer” category is listed.
All participants who completed the preassessment survey (n = 147).
Participants who were vaccinated during survey completion and endorsed the motivators and barriers to vaccination (n = 88).
Participants who were unvaccinated during survey completion and endorsed the motivators and barriers to vaccination (n = 59).
Participants who were nonhesitant (unvaccinated) during survey completion and endorsed the motivators and barriers to vaccination (n = 40).
Participants who were hesitant (unvaccinated) during survey completion and endorsed the motivators and barriers to vaccination (n = 19).
Pearson chi-square tests (categorical) and Mann-Whitney U tests (scale or nominal) were conducted to compare vaccinated and unvaccinated participants and non-hesitant and hesitant participants.
Significant values (P ≤ 0.05).
Figure 3Town hall preassessment responses to questions about COVID-19 vaccines. Abbreviation used: COVID-19, coronavirus disease 2019. Note: Percentages reflect valid percentages (denominator does not include missing and “don’t know” responses). Sample sizes: vaccinated (n = 88), unvaccinated (n = 59), nonhesitant (n = 40), hesitant (n = 19). ∗Significant at P ≤ 0.05 (Pearson chi-square test of independence).
Level of trust of information sources by vaccination and hesitancy subsamples
| Information source | Vaccinated | Unvaccinated | Nonhesitant | Hesitant | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | |||||||||||
| Not at all | A little | A great deal | Not at all | A little | A great deal | Not at all | A little | A great deal | Not at all | A little | A great deal | |||
| Doctor or health care | 2 (2.3) | 9 (10.3) | 76 (87.4) | 2 (3.5) | 5 (8.8) | 50 (87.7) | 0.87 | 2 (5.1) | 1 (2.6) | 36 (92.3) | 0 (0) | 4 (22.2) | 14 (77.8) | 0.04 |
| Faith leader | 28 (39.4) | 20 (28.2) | 23 (32.4) | 16 (31.4) | 21 (41.2) | 14 (27.5) | 0.32 | 12 (36.4) | 12 (36.4) | 9 (27.3) | 4 (22.2) | 9 (50) | 5 (27.8) | 0.53 |
| Your close friends and members of the family | 11 (13.6) | 38 (46.9) | 32 (39.5) | 7 (12.5) | 24 (42.9) | 25 (44.6) | 0.84 | 5 (13.2) | 16 (42.1) | 17 (44.7) | 2 (11.1) | 8 (44.4) | 8 (44.4) | 0.97 |
| People you go to work or class with or other people you know | 15 (18.8) | 46 (57.5) | 19 (23.8) | 11 (19.6) | 35 (62.5) | 10 (17.9) | 0.71 | 7 (18.4) | 22 (57.9) | 9 (23.7) | 4 (22.2) | 13 (72.2) | 1 (5.6) | 0.25 |
| News on the radio, TV, or in newspapers | 14 (16.9) | 43 (51.8) | 26 (31.3) | 17 (30.4) | 33 (58.9) | 6 (10.7) | 0.01 | 11 (28.9) | 22 (57.9) | 5 (13.2) | 6 (33.3) | 11 (61.1) | 1 (5.6) | 0.69 |
| Your contacts on social media | 39 (47.6) | 33 (40.2) | 10 (12.2) | 35 (63.6) | 18 (32.7) | 2 (3.6) | 0.09 | 26 (70.3) | 9 (24.3) | 2 (5.4) | 9 (50) | 9 (50) | 0 (0) | 0.12 |
| The U.S. Government | 5 (6.1) | 43 (52.4) | 34 (41.5) | 9 (16.4) | 32 (58.2) | 14 (25.5) | 0.05 | 5 (13.2) | 20 (52.6) | 13 (34.2) | 4 (23.5) | 12 (70.6) | 1 (5.9) | 0.08 |
| The U.S. Coronavirus Task Force | 2 (2.4) | 25 (30.1) | 56 (67.5) | 4 (7.3) | 19 (34.5) | 32 (58.2) | 0.29 | 1 (2.7) | 8 (21.6) | 28 (75.7) | 3 (16.7) | 11 (61.1) | 4 (22.2) | 0.001 |
| Leaders in your community | 10 (12.5) | 36 (45) | 34 (42.5) | 11 (20.4) | 33 (61.1) | 10 (18.5) | 0.01 | 6 (16.7) | 23 (63.9) | 7 (19.4) | 5 (27.8) | 10 (55.6) | 3 (16.7) | 0.63 |
| Local politicians | 25 (31.3) | 45 (56.3) | 10 (12.5) | 23 (44.2) | 28 (53.8) | 1 (1.9) | 0.06 | 14 (40) | 20 (57.1) | 1 (2.9) | 9 (52.9) | 8 (47.1) | 0 (0) | 0.57 |
| Billboards | 34 (43) | 34 (43) | 11 (13.9) | 35 (64.8) | 17 (31.5) | 2 (3.7) | 0.02 | 25 (67.6) | 10 (27) | 2 (5.4) | 10 (58.8) | 7 (41.2) | 0 (0) | 0.41 |
Note: percentages reflect valid percentages (denominator does not include missing and “don’t know” responses).
Participants who were vaccinated during survey completion and endorsed the motivators and barriers to vaccination (n = 88).
Participants who were unvaccinated during survey completion and endorsed the motivators and barriers to vaccination (n = 59).
Participants who were nonhesitant (unvaccinated) during survey completion and endorsed the motivators and barriers to vaccination (n = 40).
Participants who were hesitant (unvaccinated) during survey completion and endorsed the motivators and barriers to vaccination (n = 19).
Pearson chi-square tests were conducted to compare vaccinated and unvaccinated participants and non-hesitant and hesitant participants.
Significant values (P ≤ 0.05).
Motivators and barriers to vaccination by vaccination and hesitancy subsamples
| Motivator or barrier | Vaccinated | Unvaccinated | Nonhesitant | Hesitant | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | |||
| Motivators | ||||||||||
| I want to keep my family safe | 82 | 93.2 | 45 | 76.3 | < 0.01 | 33 | 82.5 | 12 | 63.2 | 0.1 |
| I want to keep my community safe | 71 | 80.7 | 34 | 57.6 | < 0.01 | 29 | 72.5 | 5 | 26.3 | 0.001 |
| I want to keep myself safe | 74 | 84.1 | 41 | 69.5 | 0.04 | 34 | 85 | 7 | 36.8 | < 0.001 |
| I have a chronic health problem, like asthma or diabetes | 24 | 27.3 | 3 | 5.1 | 0.001 | 2 | 5 | 1 | 5.3 | 0.97 |
| My doctor told me to get a COVID-19 vaccine | 14 | 15.9 | 3 | 5.1 | 0.04 | 3 | 7.5 | 0 | 0 | 0.22 |
| I don’t want to get really sick from COVID-19 | 61 | 69.3 | 28 | 47.5 | < 0.01 | 22 | 55 | 6 | 31.6 | 0.09 |
| I want to feel safe around other people | 69 | 78.4 | 35 | 59.3 | 0.01 | 24 | 60 | 11 | 57.9 | 0.88 |
| I believe life won’t go back to normal until most people get a COVID-19 vaccine | 61 | 69.3 | 34 | 57.6 | 0.15 | 28 | 70 | 6 | 31.6 | < 0.01 |
| Barriers | ||||||||||
| I’m allergic to vaccines | 10 | 11.4 | 1 | 1.7 | 0.03 | 0 | 0 | 1 | 5.3 | 0.14 |
| I don’t like needles | 4 | 4.5 | 6 | 10.2 | 0.18 | 6 | 15 | 0 | 0 | 0.08 |
| I’m not concerned about getting really sick from COVID-19 | 0 | 0 | 7 | 11.9 | 0.001 | 4 | 10 | 3 | 15.8 | 0.52 |
| I’m concerned about side effects from the vaccine | 23 | 26.1 | 36 | 61 | < 0.001 | 21 | 52.5 | 15 | 78.9 | 0.052 |
| I don’t think vaccines work very well | 1 | 1.1 | 5 | 8.5 | 0.03 | 3 | 7.5 | 2 | 10.5 | 0.7 |
| I don’t trust that the vaccine will be safe | 7 | 8 | 19 | 32.2 | < 0.001 | 7 | 17.5 | 12 | 63.2 | < 0.001 |
| I don’t believe the COVID-19 pandemic is as bad as some people say it is | 2 | 2.3 | 6 | 10.2 | 0.04 | 2 | 5 | 4 | 21.1 | 0.06 |
| I don’t want to pay for it | 6 | 6.8 | 3 | 5.1 | 0.67 | 2 | 5 | 1 | 5.3 | 0.97 |
| I don’t know enough about how well a COVID-19 vaccine works | 11 | 12.5 | 19 | 32.2 | < 0.01 | 11 | 27.5 | 8 | 42.1 | 0.26 |
Abbreviation used: COVID-19, coronavirus disease 2019.
Note: percentages reflect valid percentages (denominator does not include missing and “don’t know” responses).
Participants who were vaccinated during survey completion and endorsed the motivators and barriers to vaccination (n = 88).
Participants who were unvaccinated during survey completion and endorsed the motivators and barriers to vaccination (n = 59).
Participants who were nonhesitant (unvaccinated) during survey completion and endorsed the motivators and barriers to vaccination (n = 40).
Participants who were hesitant (unvaccinated) during survey completion and endorsed the motivators and barriers to vaccination (n = 19).
Pearson chi-square tests were conducted to compare vaccinated and unvaccinated participants and nonhesitant and hesitant participants on endorsement of motivators and barriers to vaccination.
Significant values (P ≤ 0.05).